This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at fraseg@mmc.org.
Get full access to this article
View all access options for this article.
References
1.
WarkentinT.E.An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemostasis.2004; 30(3): 273–283.
2.
WilliamsR.T., DamarajuL.V., MascelliM.A.Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation.2003; 107(18): 2307–2312.
3.
RiceL.Heparin-induced thrombocytopenia; myths and misconceptions. Arch Intern Med.2004; 164(18): 1961–1964.
4.
HowardP.A., BarnesB.J.An update on the diagnosis, complications, and treatment of heparin-induced thrombocytopenia. Hospital Pharmacy.2004; 39(5): 408–417.
5.
WarkentinT.E., GreinacherA.Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg.2003; 76(6): 2121–2131.
GreinacherA., EichlerP., LubenowN.Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood.2000; 96(3): 846–851.
8.
FrancisJ.L., PalmerG.J., MorooseR.Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg.2003; 75(1): 17–22.
9.
GruelY., PouplardC., NguyenP.Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol.2003; 121(5): 786–792.
10.
WarkentinT.E., LevineM.N., HirshJ.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med.1995; 332(20): 1330–1335.
11.
Lindhoff-LastE., NakovR., MisselwitzF.Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol.2002; 118(4): 1137–1142.
12.
AhmadS., JeskeW.P., WalengaJ.M.Synthetic pentasaccharides do not cause platelet activation by antiheparinplatelet factor 4 antibodies. Clin Appl Thromb Hemost.1999; 5(4): 259–266.
13.
AmiralJ., LormeauJ.C., Marfaing-KokaA.Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis.1997; 8(2): 114–117.
14.
SaviP., ChongB.H., GreinacherA.Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood.2004: prepublished online 9/23/04.
15.
BullerH.R., DavidsonB.L., DecoususH.Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med.2003; 349(18): 1695–1702.
16.
BullerH.R., DavidsonB.L., DecoususH.Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med.2004; 140(11): 867–873.
17.
BauerK.A., ErikssonB.I., LassenM.R.Fondaparinux compared with enoxaparin for the prevention of venous thromboembolis after elective major knee surgery study. N Engl J Med.2001; 345(18): 1305–1310.
18.
LassenM.R., BauerK.A., ErikssonB.I.Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet.2002; 359(9319): 1715–1720.
19.
HarenbergJ., JorgI., FenyvesiT.Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica.2004; 89(8): 1017–1018.
20.
KuoK.H.M., KovacsM.J.Successful treatment of heparin-induced thrombocytopenia with fondaparinux. Blood.2003; 102(suppl):319a.
21.
SrinivasanA.F., RiceL., BartholomewJ.R.Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med.2004; 164(1): 66–70.
22.
MerryA.F.Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. Sem Thromb Hemost.2004; 30(3): 337–346.
23.
MerryA.F., RaudkiviP.J., MiddletonN.G.Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg.2004; 77(3): 925–931.
24.
KosterA., SpiesB., ChewD.P.Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol.2004; 93(3): 356–359.
25.
HeitJ.A.The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest.2003; 124(3 suppl): S40–S48.
